← Back to headlines
BioNTech and DualityBio Drug Shows Efficacy in Endometrial Cancer
A new antibody-drug conjugate, Trastuzumab Pamirtecan, developed by BioNTech and DualityBio, has demonstrated clinically meaningful efficacy in patients with HER2-expressing, recurrent endometrial cancer. The findings suggest a promising new treatment option for this patient group.
11 Apr, 11:00 — 11 Apr, 11:00
